Meanwhile, we selected 30 NAFLD patients for validation, and the results of the study followed the same trend as the dataset, BCL2L11 expression was significantly downregulated, while NAGS, HDHD3 and RMND1 expression levels were significantly upregulated in NAFLD patients. The gene discussed is NAGS; the disease is metabolic dysfunction-associated steatotic liver disease.